Important Investor Alert for Applied Therapeutics
Investors in Applied Therapeutics, Inc. (NASDAQ: APLT) should take note of significant deadlines related to a federal securities class action lawsuit. As we delve into the recent developments affecting the company, it’s vital for stakeholders to stay informed on how these events may impact their investments.
Class Action Lawsuit Overview
The law firm of Kirby McInerney LLP is reaching out to shareholders about the upcoming February 18, 2025 deadline. This date serves as the last opportunity for investors to seek the position of lead plaintiff in this federal securities class action. The suit encompasses those who acquired the company's stocks between January 3, 2024, and December 2, 2024, a period characterized by various developments.
Recent Updates from Applied Therapeutics
Recently, on November 27, 2024, Applied Therapeutics made headlines with a press release regarding a Complete Response Letter (CRL) received from the FDA concerning its New Drug Application (NDA) for govorestat, the leading candidate. The CRL signaled that the FDA reviewed the application but identified deficiencies that prevented approval. This announcement had a severe impact on the company's stock price, resulting in a staggering drop of approximately 76% in shares.
FDA Warning Letter Revelation
A further decline in stock price followed on December 2, 2024, when Applied Therapeutics disclosed it received a warning letter from the FDA. This letter raised concerns regarding previous clinical trial issues, including electronic data capture challenges and errors in dosing during the trial's escalation phase. These revelations added to the existing investor concerns and contributed to further declines in the stock value.
Key Allegations in the Lawsuit
The recent lawsuit contends that throughout the class period, the company misled investors through positive public statements while failing to disclose critical issues, including clinical trial complications. Such actions have left shareholders vulnerable and the situation calls for a closer examination of disclosures made by Applied Therapeutics.
Engaging with Legal Counsel
If you are an investor who has recently purchased or acquired securities in Applied Therapeutics and have pertinent information, Kirby McInerney LLP encourages you to reach out. Understanding your rights and the potential implications of these developments is crucial for managing your investment effectively.
About Kirby McInerney LLP
Kirby McInerney LLP is a law firm based in New York, specializing in securities, antitrust, whistleblower, and consumer litigation. Their track record in securities litigation demonstrates a commitment to protecting shareholders, with recoveries amounting to billions of dollars. For more insights about the firm, potential clients are advised to visit their official website.
Frequently Asked Questions
What is the importance of the February 18, 2025 deadline?
This deadline is critical for investors who wish to be appointed as the lead plaintiff in the federal securities class action lawsuit against Applied Therapeutics.
What led to the decline in Applied Therapeutics’ stock price?
The stock value significantly dropped after the company announced it received a Complete Response Letter from the FDA, indicating necessary corrections before approval of their lead product candidate.
What allegations are included in the class action lawsuit?
The lawsuit alleges that Applied Therapeutics misled investors by concealing material facts about negative developments in their clinical trials while providing positive statements.
How can investors get involved in the lawsuit?
Investors can reach out to Kirby McInerney LLP to discuss their rights and explore options for joining the class action.
Who can file for lead plaintiff?
Generally, any investor who acquired Applied Therapeutics securities during the specified class period and meets certain legal criteria can apply for lead plaintiff status.
